SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis

Apr 15, 2016

SCYNEXIS, Inc. to Present at the 15th Annual Needham Healthcare Conference

Apr 6, 2016

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis

Apr 6, 2016

SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update

Mar 7, 2016

SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference

Feb 29, 2016

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Feb 3, 2016

SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

Jan 28, 2016

SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis

Dec 1, 2015

SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update

Nov 13, 2015

SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078

Nov 12, 2015